Background Recurrent medulloblastoma is a therapeutic challenge because it is almost always fatal. Studies have confi rmed that medulloblastoma consists of at least four distinct subgroups. We sought to delineate subgroup-specifi c diff erences in medulloblastoma recurrence patterns.
Introduction
Medulloblastoma is the most common malignant brain tumour of childhood. 1, 2 With multimodal therapy, consisting of surgery, craniospinal irradiation, and adjuvant chemotherapy, 5-year overall survival approaches 85% for average-risk disease and 70% for high-risk disease. [3] [4] [5] However, recurrent medulloblastoma is a great challenge, because it is almost always fatal in previously irradiated patients despite a multitude of therapies including re-resection, re-irradiation, high-dose chemotherapy with autologous stem-cell support, and enrolment in clinical trials. 6 Integrative genomic studies have shown that medulloblastoma consists of at least four subgroups (WNT, SHH, group 3, and group 4) that are clinically, transcriptionally, and genetically distinct. 2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Of these four subgroups, patients with WNT subgroup tumours have an excellent prognosis whereas patients with group 3 tumours have the worst prognosis and more commonly present with disseminated disease at diagnosis. 1, 2, 12 Although these integrative genomic studies have shown that there are signifi cant diff erences in survival between the four subgroups, little is known with respect to subgroup-specifi c anatomical and temporal characteristics of recurrence. In glioblastoma, molecular subgroup affi liation can change at recurrence, partly because of intratumoural heterogeneity based on geographical location. 19, 20 Although medulloblastoma subgroups have been shown to arise from distinct cells of origin, the stability of subgroup affi liation at recurrence remains unknown. [21] [22] [23] Moreover, the clinical behaviour of the individual subgroups at recurrence has yet to be established. As such, an understanding of subgroup-specifi c temporal and spatial details could help to develop treatment of recurrent medulloblastoma, because the next generation of subgroup-specifi c clinical trials will probably be based initially in the context of recurrent medulloblastoma.
We aimed to characterise the subgroup-specifi c clinical patterns of recurrence in medulloblastoma.
Methods

Patients
We assembled a discovery cohort (cohort 1) and, to account for unobserved variables and potential bias due to diff erent subgrouping methods, two non-overlapping validation cohorts (cohorts 2 and 3). Cohort 1 consisted of all patients with medulloblastoma with either frozen or formalin-fi xed paraffi n-embedded (FFPE) material along with clinical variables and survival data, treated between 1994 and 2012, at the Hospital for Sick Children (Toronto, ON, Canada).
Cohort 2 consisted of samples from patients with recurrent medulloblastomas from 13 Worldwide, only a minority of patients with relapsed medulloblastoma undergo a second surgery at recurrence. Therefore, most patients do not have tissue available at recurrence. We obtained matched samples from diagnosis and recurrence whenever possible, and assembled cohort 1 with the goal of acquiring as many of these paired samples as possible.
The research ethics boards at all participating centres approved the study and all samples and clinical information were obtained with consent in accordance with the research ethics board at the Hospital for Sick Children and collaborating centres.
Procedures
We extracted RNA from fresh frozen tissue using the guanidinium thiocyanate-phenol-chloroform extraction method (TRIzol, Invitrogen, Carlsbad, USA), according to the manufacturer's instructions. RNA from FFPE samples (fi ve to seven paraffi n sections per sample or the Subgroup affi liation was established using nanoString targeted gene-expression profi ling, as previously described, in all cases from cohorts 1 and 2.
14 Subgroup determination for cohort 3 was done in all samples by immunohistochemistry using the four antibody method, as described previously (WNT=nuclear β-catenin, SHH=SFRP1, group 3=NPR3, group 4=KCNA1). 9, 10, 17 Cases were ascribed a subgroup if they were immunoreactive for only one marker.
For cohorts 1 and 3, results of neuroimaging to establish the pattern of recurrence were reviewed by a multidisciplinary tumour board, which included a neuroradiologist masked to molecular subgroup, at both the Hospital for Sick Children and the Burdenko Neurosurgical Institute. The pattern of recurrence in cohort 2 was provided by individual contributing institutions on the basis of a review of neuroimaging.
Statistical analysis
We established survival after recurrence between subgroups using the Kaplan-Meier method and used a log-rank test to test for diff erences between subgroups. We plotted time to recurrence using the Kaplan-Meier method and we used the generalised Wilcoxon test to look for diff erences between subgroups attributable to the absence of censoring in these data. We used Fisher's exact test to compare binary and categorical characteristics of patients between subgroups and cohorts. We analysed continuous variables using the Kruskal-Wallis test or Mann-Whitney U test. We used StataSE (version 12) for all statistical analyses, except nanoString class prediction. Principle component analysis was done in the Partek Genomic Suite and negative matrix factorisation was done using Gene Pattern 2.0. 24 We used R (version 2.15) for nanoStringbased class prediction and normalisation of nanoString data, as previously described.
14
Role of the funding source
The funding sources of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Cohort 1 consisted of 131 patients, of whom 30 had recurrent medulloblastoma. Cohort 2 consisted of 77 patients and cohort 3 of 96 patients, all of whom had recurrent medulloblastoma. At fi rst diagnosis, the WNT subgroup was rare, occurring in one (3%) of 30 patients in cohort 1, no patients in cohort 2, and two (2%) of 96 patients in cohort 3. Specimens from the remaining patients were distributed roughly equally between SHH, group 3, and group 4 in all cohorts (table 1) . Of the 96 cases in cohort 3 subgrouped by immunohistochemistry, none were immuno reactive for more than one marker, and 39 were also subgrouped using whole genome expression profi ling or nanoString without any reclassifi cations of subgroup. Table 1 shows the demographics of all three cohorts. The adult age group (>16 years) was over-represented in cohort 2, but median age did not diff er between groups. Metastatic dissemination at diagnosis was higher in cohort 3 than in either of the other cohorts, although the diff erence was not signifi cant. Median time to recurrence was signifi cantly shorter in cohort 3 than in the other cohorts (table 2) . Histological classifi cation did not diff er across the three cohorts. When available, treatment at diagnosis for all three cohorts are summarised in table 1 and the appendix (appendix pp 8-9). Adjuvant chemotherapy regimens were all cisplatin-based across the three cohorts. Treatment in cohort 3 was uniform as per the German HIT protocols, as previously described. 25, 26 To establish whether subgroup affi liation remains stable at recurrence, 34 paired samples (fi ve pairs from cohort 1, and 29 pairs from various centres as part of cohort 2) with FFPE tissue available from the initial surgery and recurrence were analysed by nanoString. At recurrence, tissue was obtained from the primary site in 16 tumours; 18 samples were from biopsies of leptomeningeal metastases. In all 34 paired samples, subgroup affi liation remained stable between diagnosis and the corresponding local or metastatic recurrence (15 SHH, fi ve group 3, 14 group 4; fi gure 1; appendix p 10). One local recurrence was subgrouped as a group 4 at diagnosis and SHH at recurrence; however, upon review of the histological specimen by a senior neuro pathogist (AK), the recurrence was established to be a radiation-induced secondary glioblastoma and this patient was therefore excluded from all other analyses (appendix p 12). To further confi rm the fi nding that subgroup affi liation does not change, an orthogonal technique of subgroup determination using immuno histochemistry was done on 17 paired samples from the initial surgery and recurrence as part of cohort 3, using a four antibody method as previously described. 
Survival after recurrence
All subgroups 0·70 (0·00-1·99)
Data are median years (95% CI). p values calculated using the generalised Wilcoxon test. "All subgroups" includes WNT patients. *Data available for 73 of 77 patients. In all 17 paired samples, the initial pattern of immunoreactivity remained stable at recurrence, with one WNT, six SHH, four group 3, and six group 4 patients, demonstrating the same subgroup affi liation at recurrence as at diagnosis (appendix p 11). Therefore, we conclude that medulloblastoma does not change subgroup at the time of recurrence. Median time to recurrence for cohort 1 was 1·49 years (95% CI 1·09-1·90; table 2). When time to recurrence in the cohort 1 was analysed in a subgroup-specifi c manner, group 4 tumours recurred signifi cantly later than both group 3 and SHH tumours (p=0·0080, generalised Wilcoxon; appendix p 13). Of the 30 recurrences in cohort 1, six patients were alive at the time of the study with a median overall survival after recurrence of 0·70 years (95% CI 0·00-1·99, appendix p 14), calculated as the time to death or last follow-up after fi rst recurrence. There were two long-term survivors (>5 years), a WNT subgroup patient who survived for 8·47 years after recurrence and a group 4 subgroup patient who survived for 13·75 years after recurrence. Both patients were initially treated with reduced-dose craniospinal irradiation and chemotherapy. The WNT long-term survivor relapsed 1·49 years after diagnosis and was salvaged with re-irradiation and high-dose chemotherapy with autologous stem-cell support, followed by temozolomide plus etoposide at a second recurrence 1 year later. The group 4 long-term survivor was salvaged with re-resection followed by high-dose chemotherapy with autologous stem-cell support. When overall survival after recurrence in cohort 1 was analysed in a subgroupspecifi c manner, patients with group 4 tumours had a signifi cantly longer overall survival after recurrence than did those with group 3 and SHH tumours (fi gure 2A; p=0·013, log-rank; table 2).
The two fi ndings that patients with group 4 tumours recur later and have longer overall survival after recurrence than group 3 and SHH tumours were confi rmed in cohort 2 but not in cohort 3 (fi gure 2B, 2C; table 2). For all subgroups, time to recurrence was signifi cantly shorter for cohort 3 than for the cohort 1 or cohort 2 (table 2), suggesting that diff erences in therapy might account for this discrepancy; however, treatment regimens were much the same across cohorts (table 1) . Therefore time to recurrence and overall survival after recurrence might still diff er signifi cantly between subgroups.
Survival data were available in 73 of 77 cases in cohort 2. Four patients were alive 5 years after recurrence: one WIF1  TNC  GAD1  DKK2  EMX2  PDLIM3  EYA1  HHIP  ATOH1  SFRP1  IMPG2  GABRA5  EYS  MAB21L2  NRL  NPR3  KCNA1  EOMES  KHDRBS2  RBM24  UNC5D  OAS1  WIF1  TNC  GAD1  DKK2  EMX2  PDLIM3  EYA1  HHIP  ATOH1  SFRP1  IMPG2  GABRA5  EYS  MAB21L2  NRL  NPR3  KCNA1  EOMES  KHDRBS2  RBM24  UNC5D patient each with an SHH tumour and group 3 tumour and two patients with a group 4 tumour. Two patients in cohort 2, both with group 4 tumours, died of disease at 6·2 years and 7·4 years after the initial recurrence. Survival data were available for all 96 cases in cohort 3. Long-term survivors after recurrence were more common in this cohort, with 17 patients surviving more than 5 years after recurrence, of whom 15 received radiation at initial therapy. The subgroup distribution of these 17 cases was one WNT, four SHH, six group 3, and six group 4. Two recurrent WNT cases were also identifi ed in cohort 3; one was a long-term survivor of 5·4 years after recurrence (time to recurrence 3·2 years), whereas the other died 0·67 years after recurrence (time to recurrence 1·25 years). When treatment information was available, we did not identify any consistent diff erences in treatment regimens in these long-term survivors compared with the remainder of the cohort.
To establish whether the location of recurrence diff ers between subgroups, we reviewed the location of fi rst recurrence in cohort 1. The pattern of recurrence was available in all 30 recurrent cases. All patients were followed up with serial MRI of the craniospinal axis after completion of therapy as per treatment protocol. Recurrences were divided into local recurrences (tumour bed only without involvement of the cerebellar leptomeninges and when CSF examinations were available, no malignant cells in the CSF), metastatic recurrences (relapse at distant sites outside the tumour bed), and metastatic plus local recurrences (relapse at both distant sites and the tumour bed). We identifi ed nine local recurrences and 21 metastatic recurrences. When we reanalysed these data in a subgroup-specifi c manner, eight of nine local recurrences were SHH tumours, and 17 of 20 metastatic recurrences were either group 3 or group 4, with one WNT metastatic recurrence (p=0·0014 Fisher's exact test; local vs metastatic recurrence, SHH vs group 3 vs group 4; table 3, appendix p 15).
We also identifi ed this pattern in the two independent, non-overlapping validation cohorts, and the results were signifi cant (cohort 2 p=0·0013, cohort 3 p<0·0001, Fisher's exact test; table 3, appendix p 15). We identifi ed no signifi cant diff erence in the pattern of relapse between group 3 and group 4 (appendix p 15).
In an exploratory analysis combining all three cohorts, incidence of local recurrences tended to be higher in group 4 in non-irradiated patients, suggesting that nonirradiated group 4 patients might recur locally (p=0·031; table 4, appendix p 16). When comparing the location of recurrence of patients given chemotherapy only versus craniospinal irradiation (with or without adjuvant chemotherapy), we noted no diff erence between SHH and group 3 in any of the three cohorts, and we noted no diff erence in these two treatment regimens when combining all three cohorts (SHH p=0·83, group 3 p=0·34; appendix p 16). CSF examinations in fi ve of nine local recurrences in cohort 1 and in all local recurrences 1, (B) cohort 2, and (C) cohort 3 . p values were calculated using the log-rank test across the three subgroups.
in cohort 3 showed no metastatic dissemination. In cohort 2, CSF examinations were not available for all patients; however, in one local group 4 recurrence a CSF examination showed distant metastases (M1 disease). Two extraneural metastases occurred in cohort 2. The fi rst case was an SHH tumour in an adult patient who received radiation and chemotherapy and the second occurred in a child given radiation only. Three WNT tumours recurred across all three cohorts: two recurred with distant metastases only and one recurred in the tumour bed only (appendix p 8). No signifi cant diff erences were noted in either time to recurrence, or overall survival when comparing by location of recurrence in any of the three subgroups. SHH tumours recurred with metastases in 29% (18 of 62) of cases across all three cohorts. To work out whether age was a factor in disseminated relapse in SHH tumours we established the presence of metastatic recurrences by age across all three cohorts and noted no signifi cant diff erence (appendix p 17).
Metastatic dissemination at diagnosis was associated with 21% (11 of 52) of SHH tumours across all three cohorts, and was not statistically signifi cant when comparing local versus metastatic recurrences (p=0·25, appendix p 8). 39% (23 of 59 of group 3 patients and 58% (33 of 57) of group 4 patients with metastatic dissemination at relapse did not have distant metastases (ie, had M0 disease) at diagnosis (appendix p 8). We therefore conclude that SHH tumours more frequently have isolated tumour bed recurrences, and that group 3 and group 4 tumours usually recur with metastases.
Discussion
Our results show that medulloblastoma does not change subgroup at recurrence. This fi nding was not dependent on location of recurrence, because subgroup affi liation remained stable in both local tumour bed samples and metastatic samples at recurrence. We also identifi ed signifi cant diff erences across subgroups with respect to the anatomical and temporal patterns of recurrence, specifi cally SHH tumours recur mostly in the local tumour bed and group 3 and group 4 tumours recur almost exclusively with metastases. Patients with group 4 tumours also have an increased time to death after recurrence. These fi ndings have important implications in the care of patients with recurrent medulloblastoma and provide insight into the planning of future clinical trials. As far as we are aware, this study represents the largest cohort of recurrent medulloblastoma assembled so far (appendix p 3) and the largest cohort of recurrent medullo blastoma with molecular correlation (panel).
Retention of subgroup provides further evidence supporting the notion that medulloblastoma arises from distinct cells of origin within the posterior fossa, the characteristics of which are carried forward from ontogeny into oncology. Indeed, this fi nding is in agreement with murine models in which WNT, SHH, and group 3 tumours have unique cells of origin, specifi cally the lower rhombic lip, the external granule layer, and postnatal cerebellar progenitor cells, respectively. Our fi ndings suggest that group 4 tumours also arise from a yet to be identifi ed cell of origin, distinct from the other three subgroups. [21] [22] [23] Our fi ndings contrast with some initial fi ndings in glioblastoma that suggestions that subgroup affi liation can change at recurrence. 19, 20 As in breast cancer and renal cell carcinoma, metastases from medulloblastoma have been shown to be highly genetically divergent from their matched primary tumour. 16, 29, 30 Genetic divergence of medulloblastoma metastases from their primary tumour in the face of subgroup stability across both tumour types suggests that subgroup identity might be established in the cell of origin. Further investigation of paired samples from diagnosis and matched metastatic recurrences using next generation methods, such as RNA sequencing and
Local
Mixed Metastatic Cohort 1 (p=0·0014) whole genome sequencing, will be needed to establish the full spectrum of heterogeneity between primary and metastatic tumours. Previous research has suggested that local recurrences are more common in younger children, and metastatic recurrences are more common in older children. 31, 32 Protocols for treatment of infants consisting of chemotherapy only have been associated with a higher propensity for local recurrence than those including irradiation. However, our data suggest a simple, proximate explanation: this outcome is probably driven by subgroup, because SHH tumours are more common in infants and group 4 tumours are more common in older children. 7, 12 Overall, we noted no association between treatment regimen and site of recurrence, with the exception of a possible association between chemotherapy-only approaches and local recurrences in group 4 tumours. This fi nding suggests that in younger children who are not irradiated, local group 4 recurrences should not be unexpected; however, this conclusion is limited by a small sample size of non-irradiated patients with group 4 tumours (n=8) and warrants further investigation in a prospective trial. Treatment was uniform across cohorts and subgroups, with infants younger than 3 years given chemotherapy-only approaches and children older than 3 years given radiation followed by cisplatin-based adjuvant chemotherapy. Taken together, our data suggest that subgroup affi liation, rather than treatment eff ect, seems to be the primary driver of location of recurrence, particularly in patients with group 3 or SHH tumours.
A limitation of our study is the scarcity of knowledge with respect to assessments of distant metastases at relapse and absence of detailed treatment information at relapse. Future prospective studies will need to rigorously show that the CSF is free of metastatic disease in local recurrences, specifi cally in the rare situations in which local recurrences occur in group 3 and group 4 tumours, to exclude metastatic dissemination. Prospective multicentre longitudinal studies of recurrent medullo blastoma in a subgroup-specifi c manner are needed to establish whether present or future salvage therapies confer any benefi t. Our fi nding that the pattern of recurrence is highly subgroup specifi c needs prospective validation in a multicentre cooperative study of homogeneously treated patients.
Previous cross-species genomic studies have shown that metastatic medulloblastoma is a bicompartmental disease in which the metastases are highly divergent from their matched primary tumour in both human beings and mice. 16, 28 This fi nding suggests that response and susceptibility to therapy are likely to be diff erent in the primary tumour and metastases. Our data show the excellent tumour control for group 3 and group 4 medulloblastoma in the posterior fossa with existing therapies. However, the worrying fi nding that most group 3 and group 4 recurrences are metastatic, in combination with the fact that metastases are genetically divergent from the primary tumour, 16 and that medulloblastoma metastases are understudied, suggests that future basic science and clinical trials of group 3 and group 4 tumours should be more highly focused on metastases. Most patients with group 3 and group 4 tumours of average risk in our cohort were given highdose craniospinal irradiation, further reinforcing the importance of generating novel approaches to therapy in metastatic disease. Moreover, our fi nding that most group 3 and group 4 metastatic relapses do not relapse in the primary site suggests that microscopic leptomeningeal metastases not visible by neuroimaging or CSF examination are resistant to existing therapy. As such, additional local therapies targeting the primary site in the posterior fossa are unlikely to increase the proportion of patients cured for patients with group 3 or group 4 medulloblastoma. Possible strategies aimed at the metastases include intrathecal consolidation regimens in addition to existing therapies, which achieve excellent local tumour bed control.
Currently clinical trials for previously irradiated relapsed metastatic medulloblastoma are very heterogeneous and
Panel: Research in context
Systematic review
We searched PubMed and Google Scholar with the terms "medulloblastoma", "recurrent medulloblastoma", "medulloblastoma recurrences", and "medulloblastoma treatment", for reports in English, without any date restrictions. We identifi ed several studies over the past 30 years reporting the anatomical pattern of recurrence in medulloblastoma, specifi cally that recurrences can occur either in the tumour bed, along the leptomeninges, or both; however, all these previous studies are limited by both small numbers and absence of biological correlation. Several integrated genomic studies have identifi ed four subgroups of medulloblastoma with distinct demographics, genetics, transcriptomes, and outcomes; however, little is known with regards to the clinical implications of these subgroups at the time of disease recurrence.
Interpretation
As far as we are aware, our study is the largest single study of recurrent medulloblastoma and the fi rst to assess recurrent medulloblastoma in a subgroup-specifi c manner. Many researchers in paediatric neuro-oncology have suggested that medulloblastomas might recur as more aggressive subgroups (ie, an SHH or group 4 tumour becoming a group 3 tumour). In this study we showed that at the time of recurrence, medulloblastomas maintain their subgroup affi liation and that the anatomical pattern of recurrence is highly subgroup specifi c. SHH medulloblastomas almost always recur locally, suggesting that additional therapies aimed at the posterior fossa might be most benefi cial. Importantly, we showed that almost all recurrences of group 3 and group 4 medulloblastoma are metastatic, with recurrence in the posterior fossa in radiated patients being very rare. Moreover we showed that this subgroup-specifi c pattern of relapse was highly consistent across three independent cohorts, and was not dependent on therapy at diagnosis. As such, subgroup affi liation, rather than treatment eff ect, seems to be the main driver of location of recurrence. Our data for metastatic recurrence, in combination with previous reports showing that metastases are clinically and genetically distinct from the primary tumour, 16, 28 suggest that the paediatric neuro-oncology community needs to radically shift the focus away from the primary tumour towards metastases because patients with group 3 or group 4 tumours are dying almost exclusively from metastatic disease . many are at phase 2 stage. Since any future subgroupspecifi c clinical trial will probably begin with relapsed patients, trials for relapsed group 3 or group 4 medulloblastoma are poised to fail if they are based on the biology of the primary tumour. Because SHH tumours predominantly recur in the posterior fossa, consideration of a clinical trial intensifying treatment to the posterior fossa (to treat local recurrence) while simultaneously reducing craniospinal doses (because leptomeningeal failure is rare) should be considered. Trials that are being planned will help to elucidate the eff ects of inhibitors of SMO on local tumour control for patients with SHH tumours. 
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